跳至主要内容
临床试验/EUCTR2014-005599-27-NL
EUCTR2014-005599-27-NL进行中(未招募)1 期

Visualizing beta cells in morbid obese patients with T2D before and after bariatric surgery(NL51980.091.15) - Visualizing beta cells before and after bariatric surgery

Radboud University Medical Center Nijmegen0 个研究点目标入组 12 人开始时间: 2016年9月28日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - Morbid obese T2D patient who will undergone RYGB at the Rijnstate in Arnhem (BMI > 35 kg/m2)
  • - Signed informed consent
  • Mild T2D group
  • o C-peptide > 1.3 nmol/l
  • o T2D diagnosis < 2 years before RYGB
  • o Only metformin usage as anti-diabetic medication
  • Severe T2D group
  • o C-peptide < 1 nmol/l
  • o T2D diagnosis > 4 years before RYGB
  • o Insulin and/or sulfonylurea (SU) usage
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 12
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Fasting glucose < 7 mmol/l at time C-peptide was determined (Aarts et al. 2013)
  • - Known liver failure or serum liver values over 2 times normal value at the time of standard laboratory assessment.
  • - BMI > 50 kg/m2
  • - Previous treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors
  • - Pregnancy or the wish to become pregnant within 18 months
  • - Breast feeding
  • - Kidney failure, i.e. calculated creatinine clearance below 40ml/min
  • - Age < 18 years
  • - No signed informed consent

研究者

发起方
Radboud University Medical Center Nijmegen

相似试验